Trial of Divalproex for Bipolar Disorder

Authors

  • J Gordon Millichap Northwestern University Feinberg School of Medicine

DOI:

https://doi.org/10.15844/pedneurbriefs-16-10-2

Keywords:

Divalproex, Bipolar Disorder, Mania Rating Scale

Abstract

The safety and effectiveness of divalproex sodium (Depakapote®) in the treatment of 40 children and adolescents, aged 7 to 19 years, with a primary diagnosis of bipolar disorder were evaluated by open-label study (2-8 weeks) at the University of Texas, Galveston; University of Pennsylvania, Philadelphia; SUNY Stonybrook, NY; Massachusetts General Hospital, Boston; and University of Texas, San Antonio.

Published

2002-10-01

Issue

Section

Attention Deficit Disorders